News
RPTX
2.650
0.00%
0.000
Repare Therapeutics completes acquisition and goes private
TipRanks · 01/28 22:32
*News On Repare Therapeutics Inc. (RPTX) Now Under XEN.XX
Dow Jones · 01/28 22:08
Weekly Report: what happened at RPTX last week (0119-0123)?
Weekly Report · 01/26 09:23
Weekly Report: what happened at RPTX last week (0112-0116)?
Weekly Report · 01/19 09:26
Repare Therapeutics Receive Shareholders Approval Of Its Acquisition By XenoTherapeutics
Benzinga · 01/16 22:01
Press Release: Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
Dow Jones · 01/16 21:58
Weekly Report: what happened at RPTX last week (0105-0109)?
Weekly Report · 01/12 09:25
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million
TipRanks · 01/05 15:08
Weekly Report: what happened at RPTX last week (1229-0102)?
Weekly Report · 01/05 09:24
Repare Therapeutics Sells RP-3467 Program to Gilead
TipRanks · 12/29/2025 12:34
Weekly Report: what happened at RPTX last week (1222-1226)?
Weekly Report · 12/29/2025 09:23
Repare Sells Key Oncology Asset to Gilead, Lifts Expected Xeno Deal Payout
TipRanks · 12/26/2025 21:05
Wednesday Sector Leaders: Drugs, Biotechnology Stocks
NASDAQ · 12/24/2025 17:17
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million
Benzinga · 12/24/2025 13:36
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead
Dow Jones · 12/24/2025 12:33
Market-Moving News for December 24th
Benzinga · 12/24/2025 12:20
Repare Therapeutics announces Gilead to acquire RP-3467 for up to $30M
TipRanks · 12/24/2025 12:20
Repare Therapeutics Sells Cancer Drug Asset To Gilead For Up To $30M
Benzinga · 12/24/2025 12:19
Gilead to buy Repare Thera’s cancer candidate for up to $30M
Seeking Alpha · 12/24/2025 12:19
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 12/24/2025 12:05
More
Webull provides a variety of real-time RPTX stock news. You can receive the latest news about Repare Therapeutics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RPTX
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.